Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jun;40(3):240-7.
doi: 10.4093/dmj.2016.40.3.240. Epub 2016 Apr 21.

Effects of Rebamipide on Gastrointestinal Symptoms in Patients with Type 2 Diabetes Mellitus

Sejeong Park  1 , So Young Park  2 , Yu Jin Kim  2 , Soo Min Hong  1 , Suk Chon  1   3 , Seungjoon Oh  1   3 , Jeong Taek Woo  1   3 , Sung Woon Kim  1   3 , Young Seol Kim  4 , Sang Youl Rhee  1   5
Affiliations

Effects of Rebamipide on Gastrointestinal Symptoms in Patients with Type 2 Diabetes Mellitus

Sejeong Park et al. Diabetes Metab J. 2016 Jun.

Abstract

Background: Gastrointestinal (GI) symptoms are common in patients with type 2 diabetes mellitus (T2DM). Rebamipide is an effective gastric cytoprotective agent, but there are few data on its usefulness in T2DM. The aim of this study is to evaluate the improvement of GI symptoms after rebamipide treatment in patients with T2DM.

Methods: Patients with T2DM and atypical GI symptoms were enrolled. They took rebamipide (100 mg thrice daily) for 12 weeks and filled out the diabetes bowel symptom questionnaire (DBSQ) before and after rebamipide treatment. The DBSQ consisted of 10 questions assessing the severity of GI symptoms by a 1 to 6 scoring system. Changes in the DBSQ scores before and after rebamipide treatment were analyzed to evaluate any improvements of GI symptoms.

Results: A total of 107 patients were enrolled, and 84 patients completed the study. The mean age was 65.0±7.8, 26 patients were male (24.8%), the mean duration of T2DM was 14.71±9.12 years, and the mean glycosylated hemoglobin level was 6.97%±0.82%. The total DBSQ score was reduced significantly from 24.9±8.0 to 20.4±7.3 before and after rebamipide treatment (P<0.001). The DBSQ scores associated with reflux symptoms, indigestion, nausea or vomiting, abdominal bloating or distension, peptic ulcer, abdominal pain, and constipation were improved after rebamipide treatment (P<0.05). However, there were no significant changes in symptoms associated with irritable bowel syndrome, diarrhea, and anal incontinence. No severe adverse events were reported throughout the study.

Conclusion: Rebamipide treatment for 12 weeks improved atypical GI symptoms in patients with T2DM.

Keywords: Diabetes mellitus, type 2; Gastrointestinal diseases; Rebamipide.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST: No potential conflict of interest relevant to this article was reported.

Figures

Fig. 1
Fig. 1. Patients of the study.
Fig. 2
Fig. 2. Changes of the diabetes bowel symptom questionnaire (DBSQ) scores before and after rebamipide treatment (Tx). aP<0.05.
Fig. 3
Fig. 3. Comparisons of the diabetes bowel symptom questionnaire (DBSQ) score before and after rebamipide treatment (Tx), with respect to (A) sex, (B) age, (C) duration of mellitus duration (DM), (D) glycosylated hemoglobin (HbA1c) level, and (E) body mass index (BMI). Paired t-test for paired values.
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

References

    1. Bytzer P, Talley NJ, Leemon M, Young LJ, Jones MP, Horowitz M. Prevalence of gastrointestinal symptoms associated with diabetes mellitus: a population-based survey of 15,000 adults. Arch Intern Med. 2001;161:1989–1996. - PubMed
    1. Horowitz M, Dent J. Disordered gastric emptying: mechanical basis, assessment and treatment. Baillieres Clin Gastroenterol. 1991;5:371–407. - PubMed
    1. Rayner CK, Samsom M, Jones KL, Horowitz M. Relationships of upper gastrointestinal motor and sensory function with glycemic control. Diabetes Care. 2001;24:371–381. - PubMed
    1. Talley NJ, Young L, Bytzer P, Hammer J, Leemon M, Jones M, Horowitz M. Impact of chronic gastrointestinal symptoms in diabetes mellitus on health-related quality of life. Am J Gastroenterol. 2001;96:71–76. - PubMed
    1. Huber CA, Diem P, Schwenkglenks M, Rapold R, Reich O. Estimating the prevalence of comorbid conditions and their effect on health care costs in patients with diabetes mellitus in Switzerland. Diabetes Metab Syndr Obes. 2014;7:455–465. - PMC - PubMed

LinkOut - more resources